Search Videos and More
Video
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data presented by Dana-Farber's Ann Partridge, MD.
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
News
Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain
When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders.
News
Expanding Possibilities - Researchers Dive Deep to Identify Exceptional Responders
In 2020, data from a clinical trial of patients with metastatic HER2-positive breast cancer caught the attention of Dana-Farber breast oncologist Heather Parsons, MD, MPH. She noticed what she describes as a "long tail."
News
Breast Cancer Research: New Studies Show How Post-Treatment Lifestyle Choices Shape Long-Term Outcomes After Diagnosis
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
News
Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.
News
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024
Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
News
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention
Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
News
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.